Key clinical point: Infants 1 year or younger have high rates of relapse and toxicities after allogeneic hematopoietic cell transplant (allo-HCT), contributing to survival rates that have remained largely unchanged in the last 20 years.
Major finding: Three-year overall survival rate for infants with malignant conditions who received allo-HCT was 54.8% from 2000 to 2004, compared with 58.9% from 2010 to 2014.
Study details: A retrospective cohort study involving 2,498 infants with malignant and nonmalignant conditions who received allo-HCT.
Disclosures: The study was funded by the National Cancer Institute (NCI); the National Heart, Lung and Blood Institute (NHLBI); Health Resources and Services Administration; the Office of Naval Research; and a number of private pharmaceutical companies. The investigators reported financial relationships with Sangamo Therapeutics, Mallinckrodt, Takeda, Jazz, and others.
Parikh et al. JAMA Peds. 2019 March 18. doi: 10.1001/jamapediatrics.2019.0081.
Must Reads in Cellular Therapy
Haplo-HCT shows viability in DLBCL, Dreger P et al. Blood Adv. 2019 Feb 12;3(3):360-9